BHVN - Biohaven Ltd.

QQQ $ 455.25 $ 5.77 (1.29 %)

DIA $ 409.08 $ 4.58 (1.13 %)

SPY $ 546.60 $ 6.05 (1.12 %)

TLT $ 99.96 $ 0.43 (0.43 %)

GLD $ 231.58 $ 0.97 (0.42 %)

Previous Close

$ 36.38

Open

Bid

$ 36.37 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 16.45 - $ 62.21

Volume

1,069,486

Average Volume

Market Cap

2.48B

Beta (5Y Monthly)

$ 1.85

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-09-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	02-29-2024	12-31-2023	10-K
4	11-14-2023	09-30-2023	10-Q
5	07-31-2023	06-30-2023	10-Q
6	05-12-2023	03-31-2023	10-Q
7	03-23-2023	12-31-2022	10-K
8	11-09-2022	09-30-2022	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Bernstein Initiates Coverage On Biohaven w...
09/04/2024 14:25:28

Bernstein analyst William Pickering initiates coverage on Biohaven (NYSE:BHVN) with a Outperform rating and announces Price ...

RBC Capital Reiterates Outperform on Bioha...
09/04/2024 13:19:57

RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.

Cantor Fitzgerald Reiterates Overweight on...
08/19/2024 16:20:36

Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.

Biohaven May Offer And Sell Common Shares ...
08/16/2024 20:24:26

- SEC Filing

UBS Maintains Buy on Biohaven, Lowers Pric...
08/13/2024 14:36:54

UBS analyst Ashwani Verma maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $55 to $54.

Cantor Fitzgerald Reiterates Overweight on...
08/12/2024 12:52:39

Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.

Biohaven Q2 Adj $(3.50) Misses $(1.77) Est...
08/08/2024 21:51:56

Biohaven (NYSE:BHVN) reported quarterly losses of $(3.50) per share which missed the analyst consensus estimate of $(1.77) by 9...

Morgan Stanley Initiates Coverage On Bioha...
07/24/2024 09:42:28

Morgan Stanley analyst Terence Flynn initiates coverage on Biohaven (NYSE:BHVN) with a Overweight rating and announces Price...

1m-bet-on-biohaven-check-out-these-3-stocks-insiders-are-buying

$1M Bet On Biohaven? Check Out These 3 Sto...
07/22/2024 12:58:39

RBC Capital Reiterates Outperform on Bioha...
06/18/2024 12:29:39

RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.

HC Wainwright & Co. Reiterates Buy on Bioh...
05/30/2024 18:47:40

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Buy and maintains $59 price target.

Cantor Fitzgerald Reiterates Overweight on...
05/30/2024 15:39:13

Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.

HP Posts Upbeat Earnings, Joins Foot Locke...
05/30/2024 14:45:25

biohaven-stock-stumbles-as-protein-degrading-drug-falls-short-of-expectations-in-early-stage-study

Biohaven Stock Stumbles As Protein-Degradi...
05/29/2024 18:47:15

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
05/29/2024 16:31:13

whats-going-on-with-biohaven-stock-wednesday

What's Going On With Biohaven Stock Wednes...
05/29/2024 16:03:45

The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two di...

Biohaven Highlights Development And Regula...
05/29/2024 12:33:44

Reports new interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecula...

Biohaven Announces First Patient Dosed in ...
05/29/2024 12:27:55

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
05/29/2024 12:06:44

this-biotech-stock-is-poised-for-80-upside-with-breakthrough-in-obesity-drug-market-says-jpmorgan

This Biotech Stock Is Poised For 80% Upsid...
05/22/2024 02:41:37

The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the s...